Acadia Pharmaceuticals | ACAD - Operating Expenses



Acadia Pharmaceuticals reported $232.19M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
ALKERMES USD 297.68M 4.96M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Corcept Therapeutics USD 167.76M 13.96M Jun/2025
Cytokinetics USD 178.28M 21.06M Jun/2025
Eisai JPY 181.91B 7.35B Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Incyte USD 904.7M 56.97M Jun/2025
J&J USD 16.8B 8.54B Jun/2025
Moderna USD 1.04B 113M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Prothena USD 56.43M 10.59M Jun/2025
PTC Therapeutics USD 213.73M 7.86M Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025